Combination Therapy Improves Progression-Free Survival in dMMR/MSI-H Metastatic Colorectal Cancer

Combination therapy improves progression-free survival in dMMR/MSI-H metastatic colorectal cancer

Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when treated with atezolizumab plus modified FOLFOX6 and bevacizumab compared with atezolizumab alone, according to results from the NRG-GI004/SWOG S1610 COMMIT trial published recently in the Journal of Clinical Oncology.

Atezolizumab Plus Chemotherapy Improves PFS in dMMR/MSI-H Metastatic CRC

Adding mFOLFOX6 and bevacizumab to atezolizumab cut the risk of progression or death by 58% vs atezolizumab alone in dMMR/MSI-H metastatic colorectal cancer.

Combination immunotherapy and chemotherapy improves progression-free

PITTSBURGH, PA – Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when treated with atezolizumab (Tecentriq®) plus modified FOLFOX6 and bevacizumab (Avastin®) compared with atezolizumab alone, according to results from the NRG-GI004/SWOG S1610 COMMIT trial published recently […]